Targovax has appointed Dr Erik Digman Wiklund as its new chief financial officer from April this year, succeeding Oystein Soug who became the firm's chief executive officer in November 2016.
Dr Wiklund joins the Oslo, Norway-based immuno-oncology specialist from Aker Biomarine Antarctic, where he served as director of product innovation.
He also brings experience from cancer biotech Algeta ASA, and management consulting expertise from McKinsey & Company's pharma and healthcare practice.
Soug said: “We are delighted to announce the appointment of Erik as our new chief financial officer.
“He has an impressive track record in commercial and operational roles in the biotechnology industry, combined with a strong scientific background.
“Erik's breadth of expertise will be key as we approach a number of important milestones in 2017 and 2018 within our innovative clinical pipeline, designed to help patients' own immune system to fight cancer.”
OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...